RemeGen Co., Ltd. (REGMF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 11.04 means the share price is 11.04 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $6.16B is the value of all shares combined. Beta 0.72: the stock has moved about 28% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerRemeGen Co., Ltd. (REGMF) trades at $10.93. RemeGen Co., Ltd. is a biopharmaceutical company focused on developing and commercializing biologics for autoimmune, oncology, and ophthalmic diseases. Market cap: $6.16B, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for REGMF: REGMF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates REGMF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
These figures come from statements filed 12 months ago — the most recent this company has published.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
REGMF: 2/2 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
RemeGen Co., Ltd. (REGMF) Healthcare & Pipeline Overview
RemeGen Co., Ltd., a China-based biopharmaceutical company, specializes in biologics for autoimmune, oncology, and ophthalmic diseases, with key products like Telitacicept and Disitamab Vedotin. The company operates in Mainland China and the United States, focusing on unmet medical needs within these therapeutic areas, and has a market capitalization of $6.16B.
What Is the Investment Thesis for REGMF?
RemeGen Co., Ltd. presents a notable research candidate within the biotechnology sector, driven by its focus on innovative biologics and a robust pipeline targeting autoimmune, oncology, and ophthalmic diseases. The company's existing products, Telitacicept and Disitamab Vedotin, provide a foundation for revenue generation. The company's pipeline includes multiple clinical trials, including Phase III trials for RC18 in neuromyelitis optica spectrum disorder and rheumatoid arthritis. With a market capitalization of $6.16B and a profit margin of 21.8%, RemeGen demonstrates financial stability. However, as an OTC stock, REGMF has specific risks, including liquidity and disclosure. The company's success hinges on clinical trial outcomes and regulatory approvals.
Based on FMP financials and quantitative analysis
REGMF Key Highlights
Market capitalization of $6.16B reflects investor confidence in RemeGen's pipeline and commercialized products.
- Profit margin of 21.8% indicates efficient operations and successful commercialization strategies.
- Gross margin of 100.0% suggests strong pricing power and cost management in product manufacturing.
- Beta of 0.72 indicates lower volatility compared to the overall market, potentially appealing to risk-averse investors.
- The company has 2999 employees, reflecting its operational scale and capacity for research and development.
Who Are REGMF's Competitors?
REGMF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AAVXF Abivax S.A. | $139.00 | 0.00% | $10.2B | 519-signal |
| GNNSF Genscript Biotech Corporation | $4.00 | 0.00% | $8.74B | — |
| KYKOF Kyowa Kirin Co., Ltd. | $15.80 | 0.00% | $8.27B | — |
| MSMKF MatsukiyoCocokara & Co. | $14.88 | 0.00% | $5.85B | — |
| SHJBF Shanghai Junshi Biosciences Co., Ltd. | $3.35 | 0.00% | $4.84B | — |
| LQDA Liquidia Corporation | $67.97 | -1.66% | $6.04B | 965-pillar |
| LGND Ligand Pharmaceuticals Incorporated | $289.25 | +0.42% | $5.80B | 955-pillar |
| CAI Caris Life Sciences, Inc. | $24.04 | +0.04% | $6.80B | 825-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are REGMF's Key Strengths?
Innovative biologics pipeline targeting unmet medical needs.
- Existing revenue streams from Telitacicept and Disitamab Vedotin.
- Strong presence in both Mainland China and the United States.
- Experienced management team with expertise in drug development and commercialization.
What Are REGMF's Weaknesses?
Reliance on successful clinical trial outcomes and regulatory approvals.
- High R&D costs associated with drug development.
- Competition from established pharmaceutical companies.
- OTC market listing may limit access to institutional investors.
What Could Drive REGMF Stock Higher?
REGMF catalyst: Phase III clinical trial results for RC18 in neuromyelitis optica spectrum disorder expected in late 2026.
- Regulatory submissions for Disitamab Vedotin in new cancer indications planned for 2027.
- Continued expansion of commercial operations in Mainland China and the United States.
- Advancement of preclinical candidates into Phase I clinical trials throughout 2026.
- Strategic partnerships and collaborations to expand market reach and product development.
What Are the Key Risks for REGMF?
Clinical trial failures or delays could negatively impact the company's pipeline and revenue prospects.
- Regulatory setbacks or rejection of drug applications could delay or prevent commercialization.
- Competition from established pharmaceutical companies with greater resources and market share.
- Dependence on key personnel and potential loss of talent.
- Fluctuations in currency exchange rates between USD and CNY could impact financial results.
What Are the Growth Opportunities for REGMF?
- Expansion of Telitacicept (RC18) indications: RemeGen has the opportunity to expand the use of Telitacicept beyond systemic lupus erythematosus (SLE) into other autoimmune diseases such as neuromyelitis optica spectrum disorder and rheumatoid arthritis, where it is currently in Phase III clinical trials. Success in these trials and subsequent regulatory approvals could significantly increase the drug's market potential, addressing a market estimated to grow to $64 billion by 2029.
- Commercialization of Disitamab Vedotin (RC48) in multiple cancer types: Disitamab Vedotin is being developed for various cancer indications, offering RemeGen the potential to address a broad oncology market. Positive clinical trial results and regulatory approvals in different cancer types could drive substantial revenue growth. The global oncology market is projected to reach $286.6 billion by 2030, providing a significant opportunity for RemeGen.
- Advancement of pipeline candidates: RemeGen has a robust pipeline of preclinical and clinical-stage drug candidates targeting various diseases. Advancing these candidates through clinical trials and securing regulatory approvals could lead to the introduction of new products and expansion into new therapeutic areas. The company's pipeline includes RC28 for ophthalmic diseases and RC98 for solid tumors, demonstrating a diversified approach.
- Strategic partnerships and collaborations: RemeGen can pursue strategic partnerships and collaborations with other pharmaceutical and biotechnology companies to accelerate the development and commercialization of its products. Collaborations can provide access to new technologies, funding, and market expertise. This approach can help RemeGen expand its global reach and strengthen its competitive position.
- Geographic expansion: RemeGen currently operates in Mainland China and the United States. Expanding into other geographic markets, such as Europe and other parts of Asia, could provide access to new patient populations and revenue streams. This expansion would require navigating different regulatory environments and establishing distribution networks, but it could significantly increase the company's long-term growth potential.
What Threats Does REGMF Face?
- Clinical trial failures and regulatory setbacks.
- Patent expirations and generic competition.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturns and market volatility.
What Are REGMF's Competitive Advantages?
- Proprietary biologics: RemeGen's patented drug candidates provide a competitive advantage.
- Clinical pipeline: A diverse pipeline of drugs in various stages of development reduces risk.
- Regulatory expertise: Navigating regulatory pathways in China and the US creates a barrier to entry.
- Manufacturing capabilities: In-house manufacturing ensures control over supply and quality.
What Does REGMF Do?
RemeGen Co., Ltd., founded in 2008 and headquartered in Yantai, China, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative biologics. The company focuses on addressing unmet medical needs in autoimmune, oncology, and ophthalmic diseases. RemeGen's lead product, Telitacicept (RC18), is approved for the treatment of systemic lupus erythematosus (SLE), an autoimmune disease. Another key product is Disitamab Vedotin (RC48), which is being developed for various cancer indications. The company's pipeline includes several other drug candidates in various stages of clinical development, targeting conditions such as neuromyelitis optica spectrum disorder, rheumatoid arthritis, wet age-related macular degeneration, and various solid tumors. RemeGen operates in both Mainland China and the United States, seeking to expand its global reach and impact in the biopharmaceutical industry. With a team of 2999 employees, RemeGen is committed to advancing innovative therapies to improve patient outcomes.
What Products and Services Does REGMF Offer?
- Discovers and develops innovative biologics.
- Focuses on treatments for autoimmune diseases.
- Develops therapies for various types of cancer.
- Creates treatments for ophthalmic diseases.
- Conducts clinical trials to evaluate drug efficacy and safety.
- Seeks regulatory approvals for its drug candidates.
- Commercializes approved drugs in Mainland China and the United States.
How Does REGMF Make Money?
- Develops and patents novel biologic drugs.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA and NMPA.
- Manufactures and commercializes approved drugs, either directly or through partnerships.
What Industry Does REGMF Operate In?
RemeGen operates in the competitive biotechnology industry, which is characterized by high R&D costs, lengthy development timelines, and stringent regulatory requirements. The market for biologics, particularly in autoimmune and oncology, is experiencing significant growth due to the increasing prevalence of these diseases and advancements in biotechnology. RemeGen's focus on innovative biologics positions it to capitalize on these trends. Competitors include companies developing similar therapies, such as AAVXF (Ascendis Pharma A/S) and GNNSF (Genoscience Pharma).
Who Are REGMF's Key Customers?
- Patients suffering from autoimmune diseases like systemic lupus erythematosus.
- Patients diagnosed with various types of cancer.
- Patients with ophthalmic conditions such as wet age-related macular degeneration.
- Healthcare providers who prescribe RemeGen's drugs.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 71 |
| 2026-08-26 | 71 |
| 2026-08-29 | 71 |
| 2026-09-01 | 71 |
| 2026-09-04 | 71 |
| 2026-09-07 | 71 |
| 2026-09-10 | 71 |
What changed?
The score has stayed at 71.
Over the same 18 days the stock moved -9.3%.
RemeGen Co., Ltd. Financial Trajectory
RemeGen Co., Ltd. (REGMF) reported $5.18B in revenue for Q2 FY2026, reflecting 696.4% growth compared to the prior quarter. The company recorded net income of $4.32B, with diluted EPS of $7.67. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, REGMF averaged $2.58 in diluted EPS.
Company Profile
RemeGen Co., Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Yantai, CN. The company is led by CEO Jian Min Fang. REGMF has traded publicly since 2021.
How RemeGen Co., Ltd. Is Valued
RemeGen Co., Ltd. carries a market capitalization of $6.16B, placing it in the mid-cap category.
Key Financial Metrics
Return on equity for RemeGen Co., Ltd. stands at 45.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.4%, showing how much profit it generates from its asset base. A current ratio of 1.58 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
RemeGen Co., Ltd.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 20.33 places it in the safe zone, indicating low near-term bankruptcy risk.
REGMF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative biologics pipeline targeting unmet medical needs.
- Existing revenue streams from Telitacicept and Disitamab Vedotin.
- Strong presence in both Mainland China and the United States.
- Experienced management team with expertise in drug development and commercialization.
Bear Case
- Reliance on successful clinical trial outcomes and regulatory approvals.
- High R&D costs associated with drug development.
- Competition from established pharmaceutical companies.
- OTC market listing may limit access to institutional investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | CN¥5.18B | CN¥4.32B | CN¥7.67 |
| Q1 FY2026 | CN¥650M | CN¥325M | CN¥0.58 |
| Q4 FY2025 | CN¥1.51B | CN¥1.24B | CN¥2.27 |
| Q3 FY2025 | CN¥617M | -CN¥101M | -CN¥0.18 |
Q2 FY2026 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Reported in CNY
REGMF Latest News
No recent news available for REGMF.
REGMF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for REGMF.
Price Targets
Wall Street price target analysis for REGMF.
REGMF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for REGMF; grades run from A+ (80-100) to F (below 30).
Leadership: Jianmin Fang
CEO
Jianmin Fang is the CEO of RemeGen Co., Ltd. His leadership guides the company's strategic direction and operations. Fang has extensive experience in the biopharmaceutical industry, with a strong background in drug development and commercialization. His expertise spans across various therapeutic areas, including autoimmune diseases, oncology, and ophthalmology. He oversees a large workforce of 2999 employees, demonstrating his capability to manage a significant organization. Fang's leadership is crucial to RemeGen's growth and innovation in the biopharmaceutical sector.
Track Record: Under Jianmin Fang's leadership, RemeGen has successfully developed and commercialized key products such as Telitacicept and Disitamab Vedotin. He has overseen the advancement of numerous drug candidates through clinical trials, demonstrating his commitment to innovation. His strategic decisions have positioned RemeGen as a key player in the biopharmaceutical industry, focusing on unmet medical needs. Fang's tenure has been marked by significant milestones in drug development and commercial expansion.
REGMF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that RemeGen Co., Ltd. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and liquidity compared to exchange-listed stocks.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in REGMF.
- Lower trading volume can lead to price volatility and execution challenges.
- The OTC Other tier designation indicates a higher risk profile compared to exchange-listed stocks.
- Potential for fraud or manipulation due to less regulatory oversight.
- Currency exchange rate fluctuations between USD and CNY.
- Verify the company's financial statements and audit reports.
- Research the management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's regulatory filings and compliance history.
- Evaluate the company's pipeline and clinical trial results.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making investment decisions.
- RemeGen's focus on innovative biologics and a robust pipeline suggests a commitment to research and development.
- The company's existing products, Telitacicept and Disitamab Vedotin, provide a foundation for revenue generation.
- RemeGen's presence in both Mainland China and the United States indicates a global ambition.
- The company's market capitalization of $6.16B reflects investor confidence.
- The company's 2999 employees suggests a significant operational scale.
RemeGen Co., Ltd. Healthcare Stock: Key Questions Answered
Is REGMF a good stock?
Stock Expert AI does not rate REGMF buy, sell or hold. RemeGen Co., Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What does RemeGen Co., Ltd. do?
RemeGen Co., Ltd. is a biopharmaceutical company that discovers, develops, and commercializes innovative biologics for the treatment of autoimmune, oncology, and ophthalmic diseases.
What are the key factors to evaluate for REGMF?
Evaluate REGMF on fundamentals, analyst consensus, and risk factors. P/E: 11.04x vs the S&P 500's ~20-25x. However, as an OTC stock, REGMF has specific risks, including liquidity and disclosure. Not financial advice.
How frequently does REGMF data refresh on this page?
REGMF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven REGMF's recent stock price performance?
RemeGen Co., Ltd. (REGMF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative biologics pipeline targeting unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider REGMF overvalued or undervalued right now?
RemeGen Co., Ltd. (REGMF) trades at 11.04x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of REGMF?
Yes, most major brokerages offer fractional shares of RemeGen Co., Ltd. (REGMF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track REGMF's earnings and financial reports?
RemeGen Co., Ltd. (REGMF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for REGMF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or inconsistent.